نتایج جستجو برای: pd l2
تعداد نتایج: 79105 فیلتر نتایج به سال:
PURPOSE Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment. PD-1 blockade has produced significant antitumor activity in solid tumors, and similar evidence has emerged in he...
Results Here we demonstrate expression of unique core skin DC transcripts are closely associated with increased clinical aggressiveness of BCC in humans and the stratify stage 4 melanoma outcomes. In mice, loss of signature genes in DC, which include but are not limited to PD-L1/PD-L2, lead to enhanced antigen-specific immunity, decreased tumor growth, and improved anti-tumor vaccine priming to...
Protein malnutrition during early development has been correlated with cognitive and learning disabilities in children, but the neuronal deficits caused by long-term protein deficiency are not well understood. We exposed rats from gestation up to adulthood to a protein-deficient (PD) diet, to emulate chronic protein malnutrition in humans. The offspring exhibited significantly impaired performa...
Navikai gamina baltymą, vadinamą programuotos ląstelių žūties baltymo ligandu (PD-L1), kuris sąveikauja su organizmo imuninėmis ląstelėmis ir užkerta kelią imuniniam atsakui prieš vėžį. Imuninės kontrolės taško inhibitoriai, tokie kaip pembrolizumabas, prisijungia prie ląstelės (PD-1) receptoriaus blokuoja jo sąveiką ligandais PD-L1 PD-L2 bei aktyvina imuninį atsaką. Pembrolizumabas yra pirmasi...
Over the past five years immune-checkpoint inhibitors have dramatically changed the therapeutic landscape of advanced solid and hematologic malignancies. The currently approved immune-checkpoint inhibitors include antibodies to cytotoxic T-lymphocyte antigen-4, programmed cell death (PD-1), and programmed cell death ligand (PD-L1 and PD-L2). Response to immune-checkpoint inhibitors is evaluated...
Background Adenoid cystic carcinoma (ACC) is among the most common malignant salivary gland tumors. Approximately 50% of patients develop distant metastases and up to one third die within 2 years. Chemotherapy provides limited benefit, and is not associated with a survival advantage. Radiotherapy is standard for localized disease, and is also commonly used for palliation of symptomatic metastas...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید